India one of the largest contributors of global solidarity trial: WHO Chief Scientist on COVID efforts

Earlier in August, the WHO had announced the next phase in its Solidarity trial. Under this initiative, hospitalized patients are being enrolled to test three new drugs in hospitalized COVID-19 patients. Several therapies were selected by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients.

Similarly, Dr Swaminathan informed that WHO has set up a Solidarity vaccine trial platform. "We have recognised that there more vaccines which are in development need to be tested properly in clinical trials. If you have a large multicountry platform trail you can quickly enrol subjects."

"In a country like India, we can do the trial within India because we have such a huge population and every possible disease can be tested. Plus we have the capacity. We have human resources and infrastructure," she said.

"Armymen can contribute a lot more in medical research because of some inherent advantages -- more or less a...population that can be followed and excellent facilities across the military hospitals," WHO Chief Scientist added.

The Solidarity PLUS trial is a platform trial that represents the largest global collaboration among the WHO member states.

This allows the trial to assess multiple treatments at the same time using a single protocol, recruiting thousands of patients to generate robust estimates on the effect a drug may have on mortality--even moderate effects, according to WHO. 

Also Read: Omicron spreading at unprecedented rate, not seen with any previous variant: WHO